A phase I study of afatinib combined with paclitaxel and bevacizumab in patients with advanced solid tumors

PURPOSE: The combination of afatinib, an irreversible ErbB family blocker, with paclitaxel and bevacizumab was assessed in patients with advanced solid tumors. METHODS: This phase I study used a 3 + 3 design to determine the maximum tolerated dose (MTD) of afatinib combined with paclitaxel and bevac...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancer Chemother Pharmacol
Main Authors: Spicer, James, Irshad, Sheeba, Ang, Joo Ern, Enting, Deborah, Kristeleit, Rebecca, Uttenreuther-Fischer, Martina, Pemberton, Karine, Pelling, Katy, Schnell, David, de Bono, Johann
Formato: Artigo
Idioma:Inglês
Publicado em: Springer Berlin Heidelberg 2016
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5225194/
https://ncbi.nlm.nih.gov/pubmed/27872953
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3189-1
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados